The CDK9 Inhibitor, Alvocidib, Potentiates the Non-Clinical Activity of Azacytidine or Decitabine in an McL-1-Dependent Fashion, Supporting Clinical Exploration of a Decitabine and Alvocidib Combination

Blood - United States
doi 10.1182/blood-2018-99-119793
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Hematology


Related search